“rna-interference” Archives

in
Entry Author Date Location
The Medicines Co., Alnylam Take Plunge, Outline Big Test For Heart Drug 04/26/17 New York
At Arrakis, Gilman Teams With Biogen Vets to Target RNA With Pills 02/27/17 Boston
Arrowhead Nets $9.6M Investment From U.K.-Based Silence Therapeutics 01/09/17 Wisconsin
14 for ’17: Key Clinical Data To Watch For Next Year (Part 2) 12/22/16 National
With New Data, Medicines Co. Takes Long-Lasting Heart Drug to Phase 3 11/15/16 New York
Alnylam Scraps RNAi Drug After Safety Problems, Shares Plunge 10/05/16 Boston
Seeking to Join Editas, Intellia, CRISPR Tx Makes Long Awaited IPO Push 09/12/16 Boston
Alnylam Advances RNAi Drug Results After Two Years of Treatment 07/01/16 Boston
CRISPR Hits Wall Street as Editas Bags $94M in IPO 02/02/16 Boston
WaVe Joins the Crossover Party With $66M Series B for RNA Drugs 08/18/15 Boston
CRISPR Race Heats Up As Gates, Crossovers Put $120M Into Editas 08/10/15 Boston
RaNA CEO Renaud Turns To A Former Backer To Lead $55M Series B 07/23/15 Boston
East Coast Biotech Roundup: Flagship, SQZ, Epizyme, IPOs & More 06/26/15 Boston
East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More 06/12/15 Boston
East Coast Biotech Roundup: Bluebird, Sarepta, Synlogic & More 05/22/15 Boston
East Coast Biotech Roundup: Forum, Crossovers, Immuno-Oncology & More 04/24/15 Boston
Alnylam RNAi Drug Holds Up After Year of Treatment in Small Study 04/21/15 Boston
Vertex Buys Spine Drug on the QT As Part of Its Post-Hep C Makeover 02/20/15 Boston
WaVe Gets $18M to Solve RNA’s “Underappreciated” Chemistry Problem 02/02/15 Boston
Investors Line up For Westphal as Muscle Cramp Startup Upsizes IPO 01/28/15 Boston
Alnylam CEO: More Cash in Hand Is to Fuel Expansion From Within 01/21/15 Boston
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
After Unlikely Idenix Sale, Renaud Jumps to RaNA to Outfox Junk DNA 12/01/14 Boston
East Coast Biotech Roundup: Agios, Vertex, Epizyme, Celldex, & More 11/21/14 Boston
West Coast Biotech Roundup: Gilead, Juno, Hutch, Fibrogen & More 11/20/14 Seattle
With Atlas Cash and Berkeley Tools, Intellia Joins the CRISPR Fray 11/18/14 Boston
New Research Could (Finally) Remove RNAi’s Commercial Limitations 11/17/14 National
Well-Traveled Rhodes Leaves Epizyme For Atlas Venture Partnership 09/29/14 Boston
East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More 09/15/14 Boston
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
Page 1 of 8 next page »